| Literature DB >> 27353642 |
Xiaoqin Wang1,2, Zhengyu Zhang2, Gang Wu1, Changlong Nan2, Wen Shen2, Yimin Hua3, Xupei Huang4.
Abstract
BACKGROUND: Diastolic dysfunction refers to an impaired relaxation and an abnormality in a heart's filling during diastole while left ventricular systolic function is preserved. Diastolic dysfunction is commonly observed in patients with primary hypertension, diabetes and cardiomyopathies such as hypertrophic cardiomyopathy or restrictive cardiomyopathy. We have generated a restrictive cardiomyopathy (RCM) mouse model with troponin mutations in the heart to mimic the human RCM patients carrying the same mutations.Entities:
Keywords: Calcium desensitization; Diastolic dysfunction; Experimental animals; Green tea extracts; Pressure-volume relationship; Restrictive cardiomyopathy
Mesh:
Substances:
Year: 2016 PMID: 27353642 PMCID: PMC4924244 DOI: 10.1186/s12929-016-0264-1
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Fig. 1Determination of cardiac function with high resolution echocardiography in WT and RCM TG mice with or without treatment of EGCg. a Representative two-dimensional short axis views obtained from four different groups of the experimental mice. b Representative M-mode images and parameter calculation in experimental mice. c Representative images of pulsed Doppler of mitral inflow obtained from the experimental mice. LV left ventricle, RV right ventricle, E peak velocity of mitral blood inflow in early diastole, A peak velocity of mitral blood inflow in late diastole; E/A ratio; IVRT isovolumic relaxation time; IVCT isovolumetric contraction time, LVID:s left ventricular internal diameter end systole, LVID:d left ventricular internal diameter end diastole
Cardiac function measurements on WT and RCM TG mice
| WT control | WT EGCg | RCM control | RCM EGCg | |
|---|---|---|---|---|
| Parameters | ||||
| Body weight (g) | 31.67 ± 1.53 | 30.67 ± 1.61 | 27.25 ± 1.21* | 28.35 ± 1.28* |
| Heart rate (bpm) | 470.72 ± 38.12 | 481.37 ± 44.15 | 450.75 ± 50.76 | 460.17 ± 49.73 |
| Atria | ||||
| LAEDD (mm) | 2.12 ± 0.02 | 2.13 ± 0.03 | 2.29 ± 0.04** | 2.21 ± 0.05*‡ |
| LAESD (mm) | 1.67 ± 0.03 | 1.69 ± 0.04 | 1.74 ± 0.06 | 1.71 ± 0.05 |
| RAEDD (mm) | 2.11 ± 0.05 | 2.12 ± 0.06 | 2.31 ± 0.11** | 2.26 ± 0.05* |
| RAESD (mm) | 1.71 ± 0.06 | 1.69 ± 0.03 | 1.64 ± 0.04 | 1.68 ± 0.05 |
| LV end diastole | ||||
| IVS (mm) | 0.75 ± 0.04 | 0.76 ± 0.03 | 0.75 ± 0.04 | 0.74 ± 0.03 |
| LVEDD (mm) | 3.88 ± 0.07 | 3.85 ± 0.04 | 3.42 ± 0.0 6* | 3.62 ± 0.03*‡ |
| LV PW (mm) | 0.76 ± 0.02 | 0.75 ± 0.04 | 0.76 ± 0.03 | 0.73 ± 0.03 |
| LV Volume (μl) | 64.67 ± 1.71 | 63.95 ± 2.16 | 46.16 ± 2.24** | 55.92 ± 1.19*‡ |
| LV end systole | ||||
| IVS (mm) | 1.27 ± 0.03 | 1.27 ± 0.04 | 1.24 ± 0.02 | 1.25 ± 0.03 |
| LVESD (mm) | 2.05 ± 0.05 | 2.08 ± 0.06 | 1.58 ± 0.02** | 1.75 ± 0.03*‡ |
| LV PW (mm) | 1.22 ± 0.03 | 1.22 ± 0.04 | 1.21 ± 0.03 | 1.21 ± 0.02 |
| LV Volume (μl) | 13.03 ± 0.43 | 13.42 ± 0.61 | 5.96 ± 0.71 | 9.35 ± 0.80**ǂǂ |
| Ejection Fraction (%) | 79.85 ± 1.41 | 79.01 ± 1.00 | 80.33 ± 1.91 | 80.57 ± 2.16 |
| Fractional Shortening (%) | 46.72 ± 1.22 | 45.38 ± 0.66 | 47.95 ± 1.84 | 47.44 ± 2.33 |
| Mitral Doppler | ||||
| E (mm/s) | 827.61 ± 22.05 | 829.75 ± 24.22 | 740.81 ± 18.93* | 809.04 ± 25.14 |
| A (mm/s) | 657.95 ± 12.34 | 667.35 ± 16.48 | 560.33 ± 33.66 * | 633.57 ± 26.83 |
| E/A | 1.26 ± 0.04 | 1.24 ± 0.02 | 1.32 ± 0.05 | 1.27 ± 0.05 |
| IVRT (ms) | 16.41 ± 0.44 | 16.44 ± 0.46 | 21.43 ± 0.54** | 18.53 ± 0.51*‡ |
| IVCT (ms) | 10.58 ± 0.33 | 11.05 ± 0.29 | 10.36 ± 0.75 | 10.86 ± 0.53 |
Values are expressed as means ± SE for each group. LA left atrium, RA right atrium, LV left ventricle, EDD end diastolic dimension, ESD end systolic dimension, PW posterior wall thickness of LV, IVS intra-ventricular septum, EF ejection fraction of LV, FS fractional shortening of LV, E mitral Doppler E peak velocity, A mitral Doppler A peak velocity, IVRT isovolumetric relaxation time, IVCT isovolumetric contraction time. Statistical significance was determined by ANOVA followed by post hoc Newman-Keuls (SNK) tests
*p <0.05 compared to WT control, **p <0.01 compared to WT control; ǂp <0.05 compared to RCM control; ǂǂp <0.01 compared to RCM control
Fig. 2Representative pressure-volume loops obtained from catheter-based left ventricular P-V measurements in experimental mice. a Characteristic changes in left ventricular developmental pressure (LVDP) corresponding to the volume changes. Upper line indicates end systole pressure volume relationship (ESPVR) and the low line indicates end diastole pressure volume relationship (EDPVR) in different groups of mice: 1, WT mice in control group (WT control); 2, WT mice with EGCg treatment (WT EGCg); 3, cTnI193His RCM mice in control (cTnI193His control); 4, cTnI193His RCM with EGCg treatment (cTnI193His EGCg). b Normal baseline PV loops from different groups of mice. Cardiac function parameters are shown in (c), ejection fraction (EF); (d) the maximal rate of contraction (+dP/dt); (e) end-systolic pressure–volume relation slope (ESPVR); (f) the maximal rate of relaxation (−dP/dt); (g) relaxation time constant calculated by Weiss method (τ); (h) end-diastolic pressure–volume relation (EDPVR). Data are presented as means ± SE. *compared between WT and TG mice; ǂ compared between mice with or without treatment. * or ǂ P <0.05; ** or ǂǂ P<0.01
Fig. 3Inotropic responses to β-adrenergic stimulation in WT and cTnI193His RCM mice. Representative pressure-volume loops recorded at baseline (solid curve) and after administration of isoproterenol (ISO; dashed curve) in WT mice (a) and in cTnI193His RCM mice (b). c Left ventricular developed pressure (LVDP); (d) the heart rate (HR); (e) Ejection fraction (EF); (f) the maximal rate of contraction (+dP/dt max). Data are presented as means ± SE. *Significant difference compared between before and after ISO stimulation. * P <0.05
Fig. 4Levels of Ca2+ handling proteins and their phosphorylation status in myocardial cells with or without treatment of EGCg. A representative Western blot showing the levels of Ca2+ handling proteins and their phosphorylation status in WT and TG myocardial cells with or without EGCg treatment